Document is current
Any future updates will be listed below
-
Authors
Sofras, Dimitrios
Carolus, Hans
Subotić, Ana
Lobo Romero, Celia
Ennis, Craig L.
Cuypers, Lize
Lagrou, Katrien
Hernday, Aaron D.
Nobile, Clarissa J.
Rybak, Jeffrey M.
Van Dijck, Patrick
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (11J8122N, 11D7620N)
Joint Programming Initiative on Antimicrobial Resistance (G0L1622N, G0L1622N, G0L1622N, G0L1622N)
Onderzoeksraad, KU Leuven (C3/22/007, PDMT2/23/032, C3/22/007, C3/22/007, C3/22/007, C3/22/007)
National Institute of General Medical Sciences (R35GM124594, R35GM124594)
National Institute of Dental and Craniofacial Research (F31DE028488)
- License Information
-
More Information
Article History
Received: 25 April 2025
Accepted: 5 September 2025
First Online: 8 October 2025
Declarations
:
: K.L. received consultancy fees Mundipharma, speaker fees from Pfizer, Gilead, Mundipharma and FUJIFILM Wako chemicals Europe GmbH, a service fee from TECOmedical; a fee for Advisory Board participation from Pfizer and travel support from Pfizer, Gilead and AstraZeneca. C.J.N. is a cofounder of BioSynesis, Inc., a company developing inhibitors and diagnostics of biofilm formation. All other authors declare no competing interests.
